Stockscreener 앱 받기
27.16
5.15%
1.33
시간 외 거래:
28.50
1.34
+4.93%
전일 마감가:
$25.83
열려 있는:
$25.88
하루 거래량:
1.64M
Relative Volume:
1.60
시가총액:
$2.38B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-12.40
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
+10.63%
1개월 성능:
+12.60%
6개월 성능:
+40.07%
1년 성능:
-27.32%
1일 변동 폭
$25.88
$27.18
1주일 범위
$24.18
$27.18
52주 변동 폭
$13.45
$37.99
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
27.16 | 2.26B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Real time alert setup for IDEAYA Biosciences Inc. performancePortfolio Risk Summary & Weekly Breakout Watchlists - Newser
Trend analysis for IDEAYA Biosciences Inc. this week2025 Technical Patterns & Fast Entry Momentum Alerts - Newser
How to forecast IDEAYA Biosciences Inc. trends using time seriesWeekly Risk Summary & AI Powered Market Trend Analysis - Newser
Can you recover from losses in IDEAYA Biosciences Inc.2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
Using Python tools to backtest IDEAYA Biosciences Inc. strategiesEarnings Trend Report & Scalable Portfolio Growth Methods - Newser
Quantitative breakdown of IDEAYA Biosciences Inc. recent moveJuly 2025 Institutional & Verified Short-Term Plans - Newser
Real time breakdown of IDEAYA Biosciences Inc. stock performanceQuarterly Investment Review & AI Forecasted Stock Moves - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockWeekly Trend Report & Risk Adjusted Swing Trade Ideas - Newser
Measuring IDEAYA Biosciences Inc.’s beta against major indicesQuarterly Trade Review & Risk Controlled Daily Plans - Newser
IDEAYA Biosciences Inc. stock daily chart insightsTrade Entry Summary & Proven Capital Preservation Methods - Newser
Is IDEAYA Biosciences Inc. stock risky to hold nowJuly 2025 Chart Watch & Free Verified High Yield Trade Plans - خودرو بانک
Comparing IDEAYA Biosciences Inc. in custom built stock radarsDip Buying & Verified Momentum Stock Watchlist - Newser
IDEAYA enrolls first lung cancer patient in targeted therapy trial By Investing.com - Investing.com Nigeria
Will IDEAYA Biosciences Inc. continue its uptrendJuly 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
Can IDEAYA Biosciences Inc. be recession proofPortfolio Value Summary & Smart Money Movement Tracker - خودرو بانک
Is IDEAYA Biosciences Inc.’s ROIC above industry averageJuly 2025 Recap & AI Based Buy and Sell Signals - خودرو بانک
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Ideaya Biosciences stock initiated with Market Outperform rating by Citizens JMP - Investing.com Canada
What machine learning models say about IDEAYA Biosciences Inc.Market Performance Summary & Daily Momentum Trading Reports - Newser
IDEAYA Biosciences Rings the Opening Bell - Nasdaq
Ideaya submits IND for PRMT5 inhibitor - BioWorld MedTech
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - biospace.com
IDEAYA Biosciences: Barclays initiates coverage at Overweight, PT $40. - AInvest
IDEAYA enrolls first lung cancer patient in targeted therapy trial - Investing.com
IDEAYA Biosciences Expands Phase 1/2 Trial for IDE397 and Trodelvy Combination in MTAP-Deletion Non-Small Cell Lung Cancer. - AInvest
First Patient Dosed: Novel MAT2A Inhibitor + Trodelvy Combo Targets 20% of Lung Cancer Patients - Stock Titan
Barclays Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
How high can IDEAYA Biosciences Inc. stock goJuly 2025 Summary & Fast Momentum Entry Tips - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performanceJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
Is IDEAYA Biosciences Inc. trending in predictive chart modelsAnalyst Upgrade & Weekly High Return Forecasts - Newser
IDEAYA Biosciences: A High-Conviction Biotech Play with Precision Oncology Catalysts - AInvest
Transcript : IDEAYA Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Real time scanner hits for IDEAYA Biosciences Inc. explainedIndex Update & Technical Pattern Based Buy Signals - Newser
Is IDEAYA Biosciences Inc. gaining market shareWeekly Trend Summary & Stepwise Swing Trade Plans - خودرو بانک
How hedge fund analytics apply to IDEAYA Biosciences Inc. stockJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
Ideaya Biosciences stock price target raised to $74 by JPMorgan - Investing.com Canada
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
IDEAYA Biosciences submits IND for new cancer drug IDE892 By Investing.com - Investing.com Australia
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Analyzing IDEAYA Biosciences Inc. with risk reward ratio chartsJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Risk adjusted return profile for IDEAYA Biosciences Inc. analyzedMarket Trend Report & Growth-Oriented Investment Plans - Newser
Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors - The Malaysian Reserve
How to escape a deep drawdown in IDEAYA Biosciences Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
Is IDEAYA Biosciences Inc. a cyclical or defensive stock2025 Valuation Update & Safe Entry Zone Tips - خودرو بانک
Backtesting results for IDEAYA Biosciences Inc. trading strategiesTrade Signal Summary & High Win Rate Trade Tips - Newser
Will IDEAYA Biosciences Inc. stock recover after recent drop2025 Analyst Calls & Reliable Trade Execution Plans - Newser
How to monitor IDEAYA Biosciences Inc. with trend dashboardsJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):